<DOC>
	<DOCNO>NCT00172003</DOCNO>
	<brief_summary>It aim clinical study evaluate skeletal-related event rate therapy zoledronic acid patient renal cell cancer least one cancer-related bone lesion .</brief_summary>
	<brief_title>Effect Zoledronic Acid Patients With Renal Cell Cancer Bone Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>A histologically confirm diagnosis renal cell carcinoma none , one , maximum , 2 follow risk factor : 1 . Karnofsky performance status le 80 % 2 . Lactate dehydrogenase great 1.5 time upper limit normal 3 . Hemoglobin less low limit normal 4 . Absence nephrectomy Patients must evidence least one cancerrelated bone lesion . If diagnosis bone metastases bone scan magnetic resonance imaging ( MRI ) QuickScan unclear radiographic ( Xray , compute tomography [ CT ] MRI ) confirmation least one focus require . ECOG performance status 0 , 1 2 . Life expectancy ≥ 6 month Adequate liver function serum total bilirubin concentration le 1.5 x upper limit normal value Patient give write informed consent prior studyspecific procedure Only patient receive 3 less application i.v . Bisphosphonate past eligible Previous radiation therapy bone ( include therapeutic radioisotope strontium 89 ) allow . However , loci bone metastasis must present , treat radiation therapy thus assess primary secondary endpoint . Abnormal renal function evidence calculated creatinine clearance &lt; 30 ml/minute . Creatinine clearance ( CrCl ) calculate use CockcroftGault formula : CrCl = [ 140age ( year ) ] x weight ( kg ) { x 0.85 female patient } [ 72 x serum creatinine ( mg/dL ) ] Corrected ( adjust serum albumin ) serum calcium concentration &lt; 8.0 mg/dl ( 2.00 mmol/L ) ≥ 12.0 mg/dl ( 3.00 mmol/L ) Patients clinically symptomatic brain metastasis History diseases influence bone metabolism Paget 's disease primary hyperparathyroidism Severe physical psychological concomitant disease might impair compliance provision study protocol might impair assessment drug patient safety , e.g . clinically significant ascites , cardiac failure , NYHA III IV , clinically relevant pathologic finding ECG . Known hypersensitivity Zometa® ( zoledronic acid ) bisphosphonates Pregnancy lactation Women childbearing potential medically recognize form contraception ( i.e. , oral contraceptive implant , intrauterine device [ IUD ] , vaginal diaphragm sponge , condom spermicide ) Use investigational drug ( drug market indication ) within 30 day prior date study inclusion Use investigational drug ( drug market indication ) within 30 day prior date study inclusion Participation another trial Known history present abuse alcohol drug ( accept social alcohol usage exclude patient ) Subjects , opinion investigator , unlikely cooperate fully study Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure . Recent ( within 6 week ) plan dental jaw surgery ( e.g . extraction , implant ) Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Renal Cell Cancer</keyword>
	<keyword>Bone metastasis</keyword>
	<keyword>Skeletal relate event</keyword>
	<keyword>Renal Cell Cancer patient bone metastasis</keyword>
</DOC>